Other Information
−Removed: During the three months ended December 30, 2023, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows:
+Added: During the three months ended June 29, 2024, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows:
Trading Arrangement
2 unchanged sentences
Expiration Date (3)
−Removed: Basil , EVP, General Counsel
+Added: Llorens , EVP, Global Manufacturing and Supply Chain
Adoption 6/12/2024 X 14,314
4 unchanged sentences
(3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above.
−Removed: (4) Includes 12,374 shares subject to a performance share unit (“PSU”) award previously granted to Ms.
−Removed: Basil on May 18, 2021.
−Removed: The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 18, 2021 to May 17, 2024.
Restated Articles of Organization of the Company, reflecting Articles of Amendment dated August 23, 1993, August 21, 2006, July 26, 2018 and July 25, 2019 (filed as Exhibit 3.1 to the Company’s Form 8-K dated July 29, 2019 and incorporated herein by reference).
By-Laws of the Company, as amended through June 29, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K dated June 30, 2020 and incorporated herein by reference).
−Removed: Arrangement Agreement, dated as of October 10, 2023, by and among the Company, OpSens Inc.
−Removed: and 9500-7704 Quebec Inc.
−Removed: (filed as Exhibit 2.1 to the Company’s Form 8-K/A dated October 12, 2023 and incorporated herein by reference) (1).
−Removed: Form of Voting and Support Agreement (filed as Exhibit 10.1 to the Company’s Form 8-K/A dated October 12, 2023 and incorporated herein by reference) (1).
−Removed: Sixth Amendment to Lease dated February 21, 2000, made as of December 13, 2023, by and between Santa Maria Industrial Partners, L.P.
−Removed: (as successor to the lease), Haemonetics Mexico Manufacturing, S.
−Removed: and the Company, in its capacity as guarantor, for property located in Tijuana, Mexico (1).
−Removed: Office Lease Agreement, dated as of December 18, 2018, by and between OPG 125 Summer Owner (DE) LLC and the Company (1).
+Added: Indenture, dated as of May 28, 2024, between Haemonetics Corporation and U.S.
+Added: Bank National Association, as trustee.
+Added: (filed as Exhibit 4.1 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
+Added: Form of certificate representing the 2.50% Convertible Senior Notes due 2029 (included as Exhibit A to Exhibit 4.1) (filed as Exhibit 4.2 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
+Added: Second Amended and Restated Credit Agreement, dated as of April 30, 2024, by and among the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (filed as Exhibit 10.1 to the Company’s Form 8-K dated May 1, 2024 and incorporated herein by reference).
+Added: Form of Confirmation of Base Call Option Transaction (filed as Exhibit 10.1 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
+Added: Form of Confirmation of Additional Call Option Transaction (filed as Exhibit 10.2 to the Company’s Form 8-K dated May 29, 2024 and incorporated herein by reference).
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A.
6 unchanged sentences
D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
−Removed: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended July 2, 2022 formatted in inline Extensible Business Reporting Language (XBRL) includes:
+Added: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended June 29, 2024 formatted in inline Extensible Business Reporting Language (XBRL) includes:
(i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statement of Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
2 unchanged sentences
** Document furnished with this report.
−Removed: (1) Certain portions of this exhibit are considered confidential and have been omitted as permitted under SEC rules and regulations.
−Removed: The Company agrees to furnish supplementally a copy of any omitted portions to the U.S.
−Removed: Securities and Exchange Commission upon request.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HAEMONETICS CORPORATION
−Removed: February 8, 2024 By:
+Added: August 8, 2024 By:
/s/ Christopher A.
2 unchanged sentences
(Principal Executive Officer)
−Removed: February 8, 2024 By:
+Added: August 8, 2024 By:
D’Arecca, Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.